Prescient Therapeutics (ASX:PTX) Presentation, FNN Investor Event, May 2019, Sydney

Company Presentations

Prescient Therapeutics Limited (ASX:PTX) Managing Director & CEO, Steven Yatomi-Clarke discusses the company’s development pipeline, lead drug candidate PTX-200 and Phase 2 trial results in breast cancer.

Key points:

  • Developing personalised medicine to beat cancer
  • Collaborations with leading clinicians and hospitals
  • Funding in place with $9.1 million recently raised
  • Backing from life-science focused funds in US and Australia
  • Approach is to address the mutations causing cancer
  • Taking targeted therapies to the next level

For more, watch Managing Director & CEO Steven Yatomi-Clarke present.